Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 12/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8196151 | 0.88 | NISCH (0.54) | NISCHKDM4ECYP1A2ALDH1A1CYP2D6 | |
| SCHEMBL12348379 | 0.74 | NISCH (0.55) | NISCHLMNA | |
| SCHEMBL20184760 | 0.74 | PRMT1 (0.64) | NISCHLMNA | |
| SCHEMBL845603 | 0.72 | APP (0.63) | — | |
| SCHEMBL29732980 | 0.72 | APP (0.63) | — | |
| SCHEMBL5802833 | 0.72 | LMNA (0.40) | NISCHKDM4ECYP1A2ALDH1A1CYP2D6 | |
| SCHEMBL10780313 | 0.71 | TAAR1 (0.55) | NISCHKDM4ECYP1A2ALDH1A1CYP2D6 | |
| SCHEMBL22930946 | 0.70 | CHRM2 (0.37) | — | |
| SCHEMBL21664118 | 0.69 | APP (0.44) | HSD17B10LMNA | |
| SCHEMBL1307492 | 0.69 | NISCH (0.54) | NISCHKDM4ECYP1A2ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691859-B2 | Broad spectrum antibacterial compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-04-08 | — | — | US | claimed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | claimed |
| EP-1945209-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2008041966-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U.S. ARMY MEDICAL RESEARCH & MATERIEL COMMAND (US) | 2008-04-10 | — | — | WO | claimed |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2007-05-17 | — | — | US | claimed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | claimed |
| EP-1945209-B1 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | US GOV AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U S ARMY MEDICAL RESEARCH (US) | 2018-05-30 | — | — | EP | disclosed |
| US-8691859-B2 | Broad spectrum antibacterial compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2207801-B1 | METHODS OF INHIBITING VIRAL INFECTION | FUNCTIONAL GENETICS INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8207209-B2 | Methods of inhibiting viral infection | FUNCTIONAL GENETICS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120035198-A1 | Antiviral Compounds and Methods of Using Thereof | AMAN MOHAMMAD JAVAD (US) | 2012-02-09 | — | — | US | disclosed |
| US-7999001-B2 | Antiviral compounds and methods of using thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-08-16 | — | — | US | disclosed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | disclosed |
| US-20090012107-A1 | Antiviral Compounds and Methods of Using Thereof | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2009-01-08 | — | — | US | disclosed |
| WO-2008089125-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE U.S. ARMY RESEARCH INSTITUTE OF INFECTIOUS DISEASES (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1945209-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008041966-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U.S. ARMY MEDICAL RESEARCH & MATERIEL COMMAND (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2007-05-17 | — | — | US | disclosed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | disclosed |
| US-5017584-A | Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas | STERLING DRUG INC. (US) | 1991-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012107-A1 | Antiviral Compounds and Methods of Using Thereof | ZC3HAV1, MAVS, ZC3HAV1L | NISCH 91/4885KDM4E 2193/4885CYP1A2 4459/4885 |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | MPO, CAT, LPO | NISCH 33/4885KDM4E 3914/4885CYP1A2 1275/4885 |
| US-20120035198-A1 | Antiviral Compounds and Methods of Using Thereof | ZC3HAV1, MAVS, ZC3HAV1L | NISCH 91/4885KDM4E 2193/4885CYP1A2 4459/4885 |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ACHE, CTRL, MMP2 | NISCH 181/4885KDM4E 1475/4885CYP1A2 1708/4885 |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | ACHE, MMP2, TIMP3 | NISCH 268/4885KDM4E 3261/4885CYP1A2 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.